TRIAL DETAIL
Study to Investigate the Management of Hypertension and Efficacy of AZD2171 in Patients With Advanced Solid Tumours
Drug: |
||||
|---|---|---|---|---|
Trial Name: |
Study to Investigate the Management of Hypertension and Efficacy of AZD2171 in Patients With Advanced Solid Tumours |
|||
NCT#: |
||||
Conditions: |
Solid Tumors |
|||
Status: |
Completed |
|||
Phase: |
2 |
Start Date 11/01/2005 |
Age of Trial (yrs) 18.5 |
|
Treatment Phase: |
Gleevec-resistant |
|||
Drug Category: |
KIT/PDGFRA inhibitor
VEGFR inhibitor (TKI) |
|||
Strategy: |
Block KIT
Block tumor blood vessel growth |
|||
Trial Type: |
GIST not specified. GIST patients known to be enrolled. |
|||
Other Protocol IDs: |
D8480C00038, EUDRACT Number 2005-003442-33 |
|||
Sponsor: |
||||
Patient Contact: |
AstraZeneca Cancer Support Network |
|||
Contact email: |
information.center@astrazeneca.com |
|||
Contact Phone: |
1-866-992-9276 |
|||
Randomized: |
Randomized |
|||
IV or Oral: |
Oral |
|||
Trial Notes: |
The purpose of this study is to determine whether doses of 30 mg and 45 mg AZD2171 can be well tolerated without significant drug withdrawal when accompanied by a suitable hypertension management strategy or dose reduction. Locations Germany Research Site FREIBURG, Germany Research Site HAMBURG, Germany Netherlands Research Site AMSTERDAM, Netherlands Research Site NIJMEGEN, Netherlands Research Site UTRECHT, Netherlands United Kingdom Research Site Surrey, United Kingdom |
|||
Trial Links |
Trial Results |
Drug Information |
| Ongoing studies |
| The Molecular Basis of Class Side Effects Due to Treatment with Inhibitors of the VEGF/VEGFR Pathway |
Trial Sites
Name |
Address |
City |
State |
Zip |
Country |